Invitrogen™ CD180 Monoclonal Antibody (G28.8)

CD180 (RP105, Bgp95, LY64) is a type I membrane glycoprotein of Toll-like receptor (TLR) family. CD180 cytoplasmic tail is short and unlike the TLRs, it lacks the TIR domain. CD180 expression is dependent on the coexpression of its helper molecule, MD-1, and mirrors that of TLR4 on antigen-presenting cells. CD180 regulates recognition of LPS and signaling in B cells, via interacting directly with the TLR4 signaling complex, inhibiting its ability to bind microbial ligands. Ligation of CD180 by monoclonal antibodies leads to B cell activation, upregulation of CD80/CD86, and increase in cell size. CD180 consists of extracellular leucine-rich repeats (LRR) and a short cytoplasmic tail. The extracellular LRR is part of the cell surface receptor complex, RP105/MD-1. Diseases associated with CD180 dysfunction include Kawasaki Disease in children and may play a role in rheumatic disease pathology.